Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurocrine ( (NBIX) ) has issued an announcement.
Neurocrine Biosciences announced the appointment of Dr. Sanjay Keswani as Chief Medical Officer effective June 2, 2025, succeeding Dr. Eiry W. Roberts, who will remain as a strategic advisor. Dr. Keswani brings over 20 years of pharmaceutical industry experience and will lead clinical development and medical affairs, enhancing the company’s capabilities as it explores new therapeutic modalities.
More about Neurocrine
Neurocrine Biosciences is a leading neuroscience-focused biopharmaceutical company dedicated to discovering and developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders. The company offers FDA-approved treatments for conditions such as tardive dyskinesia and Huntington’s disease chorea, and has a diverse pipeline of compounds in mid- to late-phase clinical development.
YTD Price Performance: -25.37%
Average Trading Volume: 1,334,899
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.26B
See more data about NBIX stock on TipRanks’ Stock Analysis page.